When used in this chapter, the following words have the meanings hereinafter provided.
DELIVER. The actual, constructive or attempted transfer from 1 person to another of any synthetic cannabinoid, any synthetic stimulant, and/or any synthetic psychedelic/hallucinogen, whether or not there is an agency relationship and includes a sale.
DISTRIBUTE. To deliver other than by dispensing or administering any synthetic cannabinoid, any synthetic stimulant, and/or any synthetic psychedelic/hallucinogen.
PERSON. Any individual, corporation, business trust, estate, trust, partnership or association, or any other entity.
POSSESS. With the knowledge of the presence and nature of a substance, either actually or constructively in control of a substance. A person has actual possession if he or she has the substance on his or her person or within easy reach and convenient control. A person who, although not in actual possession, has the power and intention at a given time to exercise dominion or control over the substance, either directly or through another person or persons, is in the constructive possession of it.
PRODUCT CONTAINING A SYNTHETIC ALTERNATIVE DRUG. Any product containing a synthetic cannabinoid, synthetic stimulant or synthetic psychedelic/hallucinogen, as those terms are defined herein, such as, but not limited to, the examples of brand names or identifiers listed on Appendix A to this chapter.
SYNTHETIC CANNABINOID. Any laboratory-created compound that functions similar to the active ingredient in marijuana, tetrahydrocannabinol (THC), including but not limited to, any quantity
of a natural or synthetic material, compound, mixture, preparation, substance and their analog (including isomers, esters, ethers, salts, and salts of isomers) containing a cannabinoid receptor agonist, such as:
(1) JWH-007 (l-pentyl-2-methyl-3-(1-naphthoyl)indole);
(2) JWH-015 ((2-Methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone);
(3) JWH-018 (1-pentyl-3-(1-naphthoyl)indole);
(4) JWH-019 (1-hexyl-3-(naphthalene-1-oyl)indole);
(5) JWH-073 (naphthalene-1-yl-(l-butylindol-3-yl)methanone);
(6) JWH-081 (4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone);
(7) JWH-098 (4-methoxynaphthalen-l-yl(l-pentyl-2-methylindol-3-yl)methanone);
(8) JWH-122 (1Pentyl-3-(4-methyl-l-naphthoyl)indole);
(9) JWH-164 (7-methoxynaphthalen-1-yl-(pentylindol-3-yl)methanone);
(10) JWH-200 (1-(2-morpholin-4-ylethyl)indol-3-yl)-naphthalen-l-ylmethanone);
(11) JWH-203 (2-(2-chlorophenyl)-l-(1-pentylindol-3-yl)ethanone);
(12) JWH-210 (4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone);
(13) JWH-250 (1-pently-3-(2-methoxyphenylacetyl)indole);
(14) JWH-251 (l-pentyl-3-(2-methylphenylacetyl)indole);
(15) JWH-398 (l-pentyl-3-(4chloro-l-naphthoyl)indole);
(16) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-
6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol);
(17) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-
6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol);
(18) HU-308 ([(1R,2,5R)-2-[2,6-dimethoxy-4-(2-methyloctan-2-yl)phenyl]-7,7-dimethyl-4-
bicyclo[3.1.1]hept-3-enyl]methanol);
(19) HU-331 ((3-hydroxy-2[(lR,6R)-3-methyl-6-(l-methylethenyl)-2-cyciohexen-l-
yl]-5-pentyl-2,5-cyclohexadiene-l,4-dione);
(20) CP 55,940(2-[(lR,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-
methyloctan-2-yl)phenol);
(21) CP 47,497(2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol) and its
homologues;
(22) WIN 55,212-2(R-(+)-[2,3-Dihydro-5-,methyl-3-(4-morphhalinylmethyl)pyrrolo[1,2,3-
de)-1,4-benzoxazin-6-yl]-1-nepthalenylmethanone);
(23) RCS-4 ((4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone);
(24) RCS-8 (l-(l-(2-cyclohexylethyl)-lH-indol-3-yl)-2-(methoxyphenyl)ethanone).
SYNTHETIC PSYCHEDELIC/HALLUCINOGEN. Any compound that mimics the effects of any federally controlled Schedule I substance, including but not limited to, any quantity of a natural or synthetic material, compound, mixture, preparation, substance and its analog (including salts, isomers, esters, ethers and salts of isomers) containing substances that have a psychedelic/hallucinogenic effect on the central nervous system and/or brain, such as:
(1) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E);
(2) 2-(2,5-dimethoxy-4-methylphenyl)ethanamine (2C-D);
(3) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C);
(4) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I);
(5) 2-(4-(Ethylthio)-2,5-dimethoxyphenyl)ethanamine (2C-T-2);
(6) 2-(4-(Isopropylthio)-2,5-dimethoxyphenyI)ethanamine (2C-T-4);
(7) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H);
(8) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N);
(9) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)(2C-P).
SYNTHETIC STIMULANT. Any compound that mimics the effects of any federally controlled Schedule I substance, such as cathinone, methcathinone, MDMA and MDEA, including but not limited to, any quantity of a natural or synthetic material, compound, mixture, preparation, substance and its analog (including salts, isomers, and salts of isomers) containing substances that have a stimulant effect on the central nervous system, such as:
(1) 3-Fluoromethcathinone;
(2) 4-Fluoromethcathinone (other name: flephedrone);
(3) 3,4-Methylenedioxymethcathinone (other names: methylone, MDMC);
(4) 3,4-Methylenedioxypyrovalerone (other name: MDPV);
(5) 4-Methylmethcathinon (other names: mephedrone, 4-MMC);
(6) 4-Methoxymethcathinone (other names: methedrone, bk-PMMA, PMMC);
(7) 4-Ethylmethcathinone (other name: 4-EMC);
(8) Ethcathinone;
(9) Beta-keto-N-methylbenzodioxyolylpropylamine (other names: butylone, bk-MBDB);
(10) Napthylpyrovalerone (other names: naphyrone, NRG-1);
(11) N,N-dimethylcathinone (other name: metamfepramone);
(12) Alpha-pyrrolidinopropiophenone (other name: alpha-PPP);
(13) 4-methoxy-alpha-pyrrolidinopropiophenone (other name: MOPPP);
(14) 3,4-methylenedioxy-alpha-pyrrolidinopropiophenone (other name: MDPPP);
(15) Alpha-pyirrolidinovalerophenone (other name: alpha-PVP);
(16) 6,7-kihydro-5H-indeno(5,6-d)-l,3-dioxal-6-amine (other name: MDAI);
(17) Any compound that is structurally derived from 2-amino-1-phenyl-1-propanone by modification or substitution in any of the following ways:
(a) In the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl, or halide substituents, whether or not further substituted in the phenyl ring by 1 or more other univalent substituents;
(b) At the 3-position with an alkyl substituent;
(c) At the nitrogen atom with alkyl, dialkyl, benzyl or methoxybenzyl groups; or
(d) By inclusion of the nitrogen atom in a cyclic structure.
(Ord. 2012-04, passed 1-24-2012)